Treatment of hypertension with bretylium tosylate

A selective sympathetic inhibitor
      This paper is only available as a PDF. To read, Please Download here.


      Results of treatment of 27 hypertensive patients with bretylium tosylate, a new drug which selectively inhibits the sympathetic nervous system, indicate that this is an effective and useful hypotensive agent only if it is combined with other hypotensive drugs, especially diuretics for oral administration. Combination therapy permitted better control of the blood pressure with smaller doses of bretylium and prevented development of tolerance to bretylium that was observed in many cases when this agent was used alone.
      If bretylium becomes available in this country, its use can be recommended for treatment of patients with mild to moderate hypertension whose blood pressure does not respond satisfactorily to combination therapy with an oral diuretic and hydralazine or who cannot tolerate hydralazine. It should always be given in conjunction with a diuretic for oral administration. When hypertension is severe, guanethidine is the agent of choice because it is more potent than bretylium.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Schirger A.
        • Gifford Jr., R.W.
        Guanethidine, a new antihypertensive agent: experience in the treatment of 36 patients with severe hypertension.
        in: Proc. Staff Meet., Mayo Clin.37. 1962: 100
        • Boura A.L.A.
        • Green A.F.
        Actions of bretylium: adrenergic neurone blocking and other effects.
        Brit. J. Pharmacol. 1959; 14: 536
        • Blair D.A.
        • Glover W.E.
        • Kidd B.S.L.
        • Roddie I.C.
        Peripheral vascular effects of bretylium tosylate in man.
        Brit. J. Pharmacol. 1960; 15: 466
        • Brodie B.B.
        • Kuntzman R.
        Pharmacological consequences of selective depletion of catechol amines by antihypertensive agents.
        Ann. New York Acad. Sc. 1960; 88: 939
        • Boura A.L.A.
        • Green A.F.
        • McCoubrey A.
        • Laurence D.R.
        • Moulton R.
        • Rosenheim M.L.
        Darenthin, hypotensive agent of a new type.
        Lancet. 1959; 2: 17
        • Dollery C.T.
        • Emslie-Smith D.
        • McMichael J.
        Bretylium tosylate in the treatment of hypertension.
        Lancet. 1960; 1: 296
        • Hodge J.V.
        • Smirk F.H.
        Hypotensive action of bretylium tosylate (Darenthin).
        Am. Heart J. 1960; 60: 539
        • Montuschi E.F.D.
        • Pearson H.E.S.
        • Wilson L.L.
        Treatment of severe hypertension with bretylium tosylate.
        Brit. M. J. 1960; 2: 1199
        • Hurley R.E.
        • Page I.H.
        • Dustan H.P.
        Bretylium tosylate as an antihypertensive drug.
        J.A.M.A. 1960; 172: 2081
        • Lowther C.P.
        • Turner R.W.D.
        Sympathetic blockade in treatment of hypertension: Clinical trial of bretylium tosylate.
        Brit. M. J. 1960; 2: 1049
        • Dollery C.T.
        • Emslie-Smith D.
        • McMichael J.
        Bretylium tosylate in the treatment of hypertension.
        Lancet. 1960; 2: 261
        • Wolff F.W.
        Adrenergic blocking agents in the treatment of hypertension.
        J. Chron. Dis. 1961; 13: 133
        • Campbell E.D.
        • Montuschi E.
        Muscle weakness caused by bretylium tosylate.
        Lancet. 1960; 2: 789
        • Freis E.D.
        • Sugiura T.
        • Liptak D.
        Selective inhibition of the sympathetic nervous system in man with bretylium tosylate, a new antihypertensive agent.
        Circulation. 1960; 22: 191
        • Soloff L.A.
        • Reidenberg M.
        • Winters Jr., W.L.
        • Bello C.T.
        Clinical experience with bretylium tosylate.
        Ann. New York Acad. Sc. 1960; 88: 1003